NLRP3 and glomerular disorder: In the work of Ren et al, CC ameliorated renal damage of rats with early obesity‐related glomerulopathy by interfering the activation of NLRP3 inflammasome, and this effect was confirmed to be related to coptisine, the main constituent of CC.52 Coptisine (1‐30 μmol/L, 3.75 hours) was reported to inhibit caspase‐1 cleavage in LPS plus ATP/MSU/Nigericin through preventing NLRP3 inflammasome priming and assembling in stimulated Raw 264.7 macrophages.53